Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 206Colonic Neoplasms 89Rectal Neoplasms 88Stomach Neoplasms 57Pancreatic Neoplasms 49Neoplasms 42Esophageal Neoplasms 42Neoplasm Metastasis 39Unspecified Adult Solid Tumor, Protocol Specific 30Lung Neoplasms 28Glioblastoma 27Brain Neoplasms 26Carcinoma, Non-Small-Cell Lung 24Central Nervous System Neoplasms 23Glioma 22Small Cell Lung Carcinoma 21Neuroblastoma 20Astrocytoma 18Adenocarcinoma Of Esophagus 18Esophageal Squamous Cell Carcinoma 17Gliosarcoma 16Breast Neoplasms 15Rhabdomyosarcoma 13Oligodendroglioma 12Sarcoma 11Adenocarcinoma 10Medulloblastoma 9Carcinoma, Hepatocellular 9Sarcoma, Ewing 8Gastrointestinal Neoplasms 8

Interventions

Nivolumab 13Surveys and Questionnaires 6Ipilimumab 6linrodostat 5Standard of Care 5Paclitaxel 5Bevacizumab 5Sirolimus 4Pemetrexed 4Interviews as Topic 4Gemcitabine 4Docetaxel 4ARRY-334543 4temsirolimus 3relatlimab 3Erlotinib Hydrochloride 3Cetuximab 3Carboplatin 3regorafenib 2anlotinib 2abemaciclib 2Vorinostat 2Trastuzumab 2Sorafenib 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Dasatinib 2Cyclophosphamide 2vorolanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Cancer × Irinotecan × Clear all
NCT00708773 2017-01-04

Genotype-Directed Dose-Escalation Study of Irinotecan in Patients With Advanced Solid Tumors

University of Chicago

Phase 1 Completed
68 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡